{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:02:41Z","timestamp":1753891361737,"version":"3.41.2"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070922"],"award-info":[{"award-number":["32070922"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Human respiratory syncytial virus (RSV) is a ubiquitous pediatric pathogen causing serious lower respiratory tract disease worldwide. No licensed vaccine is currently available. In this work, the coding gene for mDS-Dav1, the full-length and prefusion conformation RSV fusion glycoprotein (F), was designed by introducing the stabilized prefusion F (preF) mutations from DS-Cav1 into the encoding gene of wild-type RSV (<jats:italic>wt<\/jats:italic>RSV) F protein. The recombinant adenovirus encoding mDS-Cav1, rChAd63-mDS-Cav1, was constructed based on serotype 63 chimpanzee adenovirus vector and characterized <jats:italic>in vitro<\/jats:italic>. After immunizing mice <jats:italic>via<\/jats:italic> intranasal route, the rChAd63-mDS-Cav1 induced enhanced neutralizing antibody and F-specific CD8<jats:sup>+<\/jats:sup> T cell responses as well as good immune protection against RSV challenge with the absence of enhanced RSV disease (ERD) in BALB\/c mice. The results indicate that rChAd63-mDS-Cav1 is a promising mucosal vaccine candidate against RSV infection and warrants further development.<\/jats:p>","DOI":"10.3389\/fmicb.2022.1041338","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T13:57:10Z","timestamp":1668779830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The protective immunity induced by intranasally inoculated serotype 63 chimpanzee adenovirus vector expressing human respiratory syncytial virus prefusion fusion glycoprotein in BALB\/c mice"],"prefix":"10.3389","volume":"13","author":[{"given":"Lei","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Qing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Ning","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Peng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Lei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie-Mei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Hui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Sheng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2022.02.005","article-title":"Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2","volume":"185","author":"Afkhami","year":"2022","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/mt.2016.83","article-title":"Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol. Ther."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00705-016-2880-1","article-title":"Taxonomy of the order Mononegavirales: update 2016","volume":"161","author":"Afonso","year":"2016","journal-title":"Arch. Virol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"eabl8213","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci. Adv."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e02437","DOI":"10.1128\/jvi.02437-16","article-title":"Characterization of pre-F-GCN4t, a modified human respiratory syncytial virus fusion protein stabilized in a noncleaved Prefusion conformation","volume":"91","author":"Blais","year":"2017","journal-title":"J. Virol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the global burden of disease Study 2016","volume":"18","author":"Collaborators","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1203\/PDR.0b013e318220a553","article-title":"A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease","volume":"70","author":"Feltes","year":"2011","journal-title":"Pediatr. Res."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0022-3476(80)80799-2","article-title":"Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity","volume":"96","author":"Fishaut","year":"1980","journal-title":"J. Pediatr."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.bbrc.2009.02.075","article-title":"Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB\/c mice","volume":"381","author":"Fu","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/archpedi.1986.02140200053026","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am. J. Dis. Child."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jinf.2019.02.003","article-title":"Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults","volume":"78","author":"Green","year":"2019","journal-title":"J. Infect."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e008748","DOI":"10.1136\/bmjopen-2015-008748","article-title":"Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-Centre, phase 1 clinical trial in healthy adults","volume":"5","author":"Green","year":"2015","journal-title":"BMJ Open"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3389\/fimmu.2018.03175","article-title":"A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection","volume":"9","author":"Hartnell","year":"2018","journal-title":"Front. Immunol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"ref19","first-page":"e155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","author":"Jeyanathan","year":"2022"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.antiviral.2017.05.005","article-title":"A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus","volume":"144","author":"Jiao","year":"2017","journal-title":"Antivir. Res."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat. Commun."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/infdis\/jiw453","article-title":"A randomized, controlled, observer-blinded phase 1 Study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant","volume":"215","author":"Langley","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1038\/s41467-021-27063-4","article-title":"Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization","volume":"12","author":"Lapuente","year":"2021","journal-title":"Nat. Commun."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/INF.0b013e3181a3ea71","article-title":"Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus","volume":"28","author":"Larranaga","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e01512","DOI":"10.1128\/JVI.01512-20","article-title":"A parainfluenza virus vector expressing the respiratory syncytial virus (RSV) Prefusion F protein is more effective than RSV for boosting a primary immunization with RSV","volume":"95","author":"Liang","year":"2020","journal-title":"J. Virol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/v10010038","article-title":"A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response","volume":"10","author":"Ma","year":"2018","journal-title":"Viruses"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1099\/vir.0.83300-0","article-title":"Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection","volume":"89","author":"Mapletoft","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"16271","DOI":"10.1038\/nmicrobiol.2016.271","article-title":"A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein","volume":"2","author":"Mousa","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"6112","DOI":"10.1016\/j.vaccine.2019.07.089","article-title":"Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: structure, antigenic profile, immunogenicity, and protection","volume":"37","author":"Patel","year":"2019","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e00560","DOI":"10.1128\/JVI.00560-17","article-title":"Parainfluenza virus 5 expressing wild-type or Prefusion respiratory syncytial virus (RSV) fusion protein protects mice and cotton rats from RSV challenge","volume":"91","author":"Phan","year":"2017","journal-title":"J. Virol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41541-018-0084-2","article-title":"Safety and efficacy of novel malaria vaccine regimens of RTS,S\/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP","volume":"3","author":"Rampling","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/infdis\/jiab003","article-title":"Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge Study","volume":"226","author":"Sadoff","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/infdis\/jiab003","article-title":"Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge Study","volume":"226","author":"Sadoff","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e1006810","DOI":"10.1371\/journal.ppat.1006810","article-title":"Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection","volume":"14","author":"Schmidt","year":"2018","journal-title":"PLoS Pathog."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41385-019-0243-4","article-title":"Pre-existing neutralizing antibodies prevent CD8 T cell-mediated immunopathology following respiratory syncytial virus infection","volume":"13","author":"Schmidt","year":"2020","journal-title":"Mucosal Immunol."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa2116154","article-title":"Vaccine efficacy in adults in a respiratory syncytial virus challenge Study","volume":"386","author":"Schmoele-Thoma","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1016\/j.vaccine.2011.03.042","article-title":"Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China","volume":"29","author":"Sun","year":"2011","journal-title":"Vaccine"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e0208328","DOI":"10.1371\/journal.pone.0208328","article-title":"First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children","volume":"13","author":"Tiono","year":"2018","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"100101","DOI":"10.1016\/j.metop.2021.100101","article-title":"Vaccine induced thrombotic thrombocytopenia: the shady chapter of a success story","volume":"11","author":"Tsilingiris","year":"2021","journal-title":"Metabol Open"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 safety and immunogenicity Study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding Prefusion F (Ad26.RSV.preF) in adults aged >\/=60 years","volume":"222","author":"Williams","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jviromet.2018.04.001","article-title":"DNA assembly technique simplifies the construction of infectious clone of fowl adenovirus","volume":"257","author":"Zou","year":"2018","journal-title":"J. Virol. Methods"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.1041338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T13:57:14Z","timestamp":1668779834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.1041338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":51,"alternative-id":["10.3389\/fmicb.2022.1041338"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.1041338","relation":{},"ISSN":["1664-302X"],"issn-type":[{"type":"electronic","value":"1664-302X"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"article-number":"1041338"}}